8-K: UroGen Pharma Reports Strong 2025 Results, ZUSDURI Launch On-Track

UroGen Pharma announced its Q4 and full-year 2025 financial results, highlighting the successful launch of ZUSDURI and robust JELMYTO sales.

Summary

• The commercial launch of ZUSDURI is on-track, generating $15.8 million in net sales in 2025 during its initial launch period.
• A permanent J Code for ZUSDURI became effective on January 1, 2026, which is expected to streamline reimbursement and support broader patient access.
• JELMYTO achieved net product sales of $94.0 million in 2025, representing a 7% year-over-year underlying demand sales growth.
• UroGen refinanced its existing term loan with Pharmakon Advisors, securing an immediate $200 million in non-dilutive capital and an optional $50 million by June 30, 2027, at a fixed interest rate of 8.25%.
• The Phase 3 UTOPIA trial for UGN-103 demonstrated a 77.8% three-month complete response rate, with an NDA submission planned for the second half of 2026 and potential FDA approval in 2027.
• Enrollment for the UGN-104 Phase 3 clinical trial is expected to be completed by the end of 2026.
• Investigational New Drug (IND)-enabling studies for UGN-501 are ongoing, with an IND submission and Phase 1 trial initiation targeted by the end of 2026.
• Total revenue for the full year ended December 31, 2025, was $109.8 million, a 21% increase from $90.4 million in 2024.
• The company reported a net loss of $153.5 million, or ($3.19) per basic and diluted share, for 2025, compared to a net loss of $126.9 million, or ($2.96) per share, in 2024.
• Cash, cash equivalents, and marketable securities totaled $120.5 million as of December 31, 2025.
• Guidance for full-year 2026 JELMYTO net product sales is set between $97 million and $101 million, implying 3% to 7% year-over-year growth.
• Full-year 2026 operating expenses are expected to be in the range of $240 million to $250 million, including $20 million to $24 million in non-cash share-based compensation.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update, reflecting successful product launches, strong pipeline progress, and a strengthened financial position through non-dilutive financing, despite an expected increase in net loss due to commercialization and R&D investments.

Positives

• ZUSDURI's commercial launch is on-track, achieving $15.8 million in net sales in its initial launch year (2025).
• The permanent J Code for ZUSDURI became effective on January 1, 2026, expected to significantly improve reimbursement confidence and broader patient uptake.
• JELMYTO demonstrated robust performance with $94.0 million in net product sales in 2025, reflecting a 7% year-over-year underlying demand growth.
• Successful refinancing of the term loan with Pharmakon Advisors provides $200 million in immediate non-dilutive capital and an optional $50 million, strengthening the balance sheet at a favorable fixed interest rate of 8.25%.
• UGN-103's Phase 3 UTOPIA trial showed a compelling 77.8% three-month complete response rate, consistent with previous trials.
• The FDA has agreed with the regulatory plan for UGN-103, paving the way for an NDA submission in the second half of 2026.
• Total revenue increased by 21% year-over-year to $109.8 million in 2025, driven by ZUSDURI's launch and JELMYTO's growth.
• Advancing a robust pipeline with UGN-103, UGN-104, and UGN-501, indicating future growth potential and addressing unmet medical needs.

Negatives

• Net loss increased to $153.5 million in 2025 from $126.9 million in 2024.
• Net loss per ordinary share increased to ($3.19) in 2025 from ($2.96) in 2024.
• Research and development (R&D) expenses rose to $67.1 million in 2025 from $57.1 million in 2024, primarily due to ZUSDURI manufacturing costs, Phase 3 trials, and UGN-501 acquisition.
• Selling, general and administrative (SG&A) expenses increased significantly to $155.1 million in 2025 from $121.2 million in 2024, driven by ZUSDURI commercial activities and sales force expansion.
• Cash, cash equivalents, and marketable securities decreased to $120.5 million as of December 31, 2025, from $241.7 million as of December 31, 2024.
• Total shareholders' deficit widened to $(105.5) million as of December 31, 2025, from $(8.8) million as of December 31, 2024.

Risks

• Clinical results may not be indicative of results that may be observed in the future, including in larger populations.
• Potential safety and other complications related to UroGen's products.
• Risks related to UroGen's and its licensors' ability to protect their respective patents and other intellectual property, including that pending patent applications may not be successful.
• The ability to maintain regulatory approval for products.
• Complications associated with commercialization activities.
• Labeling limitations on products.
• Competition in UroGen's industry.
• The scope, progress, and expansion of developing and commercializing UroGen's products and product candidates.
• The size and growth of the market(s) for products and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures.
• UroGen's ability to attract or retain key management, members of the board of directors, and other personnel.
• RTGel technology and ZUSDURI may not perform as expected.
• New data relating to ZUSDURI, including from spontaneous adverse event reports and the ongoing ENVISION trial, may result in changes to the product label, adversely affect sales, or result in withdrawal from the market.
• The potential for payors to delay, limit, or deny coverage for ZUSDURI.
• The data from the UTOPIA trial may not be sufficient to support approval of UGN-103.
• UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology.
• The impacts of general macroeconomic and geopolitical conditions on UroGen's business and financial position.

Future Outlook

UroGen Pharma anticipates 2026 to be a pivotal year for the ZUSDURI launch, expecting accelerated physician uptake and adoption, with ZUSDURI projected to reach over $1 billion in peak sales. The company plans to submit an NDA for UGN-103 in the second half of 2026, with potential FDA approval in 2027, and aims to explore label expansion for UGN-103. Enrollment for the UGN-104 Phase 3 trial is expected to be completed by the end of 2026, and an IND for UGN-501 is targeted for submission by the end of 2026, initiating a Phase 1 trial. JELMYTO net product sales for 2026 are guided to be between $97 million and $101 million, representing 3% to 7% growth.

Management Comments

• "2025 was a tremendously successful and transformative year for UroGen, highlighted by the FDA approval and commercial launch of ZUSDURI, the first and only approved medicine for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer."
• "2026 is a pivotal year for the ZUSDURI launch, and we are encouraged by the early post-J Code trajectory. As expected, we are seeing an acceleration across key launch indicators, including physician uptake and adoption."
• "We believe ZUSDURI is well positioned to address a significant unmet need and represents a greater than $1 billion peak sales opportunity."
• "We are advancing our pipeline with meaningful momentum across our next-generation clinical programs, UGN-103 and UGN-104. The UTOPIA trial evaluating UGN-103 demonstrated compelling complete response results consistent with the ENVISION trial, and we remain on-track to submit an NDA in the second half of 2026."
• "Following the refinancing of our term loan agreement with Pharmakon, we have further strengthened our balance sheet, and believe we are well-positioned to execute on our long-term growth strategy and build upon our leadership in uro-oncology."

Industry Context

StockSavvy.ai notes that UroGen Pharma operates in the competitive uro-oncology space, where innovation in non-surgical treatments for bladder and upper tract urothelial cancers is highly valued. The successful launch of ZUSDURI and the continued growth of JELMYTO position UroGen as a key player, especially with its proprietary RTGel technology offering sustained-release advantages. The pipeline advancements with UGN-103, UGN-104, and UGN-501 indicate a strategic focus on expanding its market presence and addressing unmet needs, aligning with broader industry trends towards less invasive and more targeted cancer therapies.

Comparison to Industry Standards

• The 77.8% three-month complete response rate for UGN-103 in the UTOPIA trial is described as "compelling" and "consistent with the ENVISION trial," suggesting strong efficacy within its therapeutic class for recurrent LG-IR-NMIBC.
• ZUSDURI's projected "greater than $1 billion peak sales opportunity" indicates management's belief in its significant market potential, comparable to other successful specialty oncology drugs.
• The 7% year-over-year underlying demand growth for JELMYTO is a solid performance for an established product in the specialty pharmaceutical market, demonstrating sustained market acceptance.

Stakeholder Impact

• Shareholders: Potential for increased value due to successful product launches, pipeline advancements, and strengthened balance sheet, but also increased net loss and cash burn.
• Patients: Improved access to innovative treatments for LG-IR-NMIBC (ZUSDURI) and LG-UTUC (JELMYTO), with promising next-generation therapies in the pipeline.
• Healthcare Providers: Streamlined reimbursement for ZUSDURI with the new J Code, potentially increasing adoption and ease of prescribing.
• Employees: Continued investment in commercial activities and R&D suggests stable to growing employment opportunities, particularly with sales force expansion.
• Creditors (Pharmakon Advisors): Refinanced debt facility with clear repayment terms and additional tranches.

Next Steps

• Continue commercial launch of ZUSDURI, leveraging the permanent J Code for broader uptake.
• Submit New Drug Application (NDA) for UGN-103 in the second half of 2026.
• Seek potential FDA approval for UGN-103 in 2027.
• Explore label expansion opportunities for UGN-103, including high-grade NMIBC and as an adjuvant to TURBT in IR-NMIBC patients.
• Complete enrollment for the UGN-104 Phase 3 clinical trial by the end of 2026.
• Submit an Investigational New Drug (IND) application for UGN-501 by the end of 2026.
• Initiate a Phase 1 trial for UGN-501 by the end of 2026.
• Evaluate several modes of administration for UGN-501, including RTGel technology.
• Explore UGN-501's potential in a broader range of cancers beyond the genitourinary system.
• Potentially draw a second tranche of $50 million from Pharmakon Advisors by June 30, 2027.
• Host a conference call and webcast on March 2, 2026, at 10:00 AM ET to discuss results.

Key Dates

Recommendation

The company shows strong operational progress with ZUSDURI's on-track launch and JELMYTO's continued growth, alongside promising pipeline developments and a strengthened balance sheet through non-dilutive financing. However, the significant increase in net loss and cash burn, coupled with a substantial decrease in cash reserves year-over-year, warrants caution. While the long-term outlook is positive with potential for ZUSDURI to reach $1 billion in peak sales, the current financial performance suggests a "hold" position until there is clearer evidence of ZUSDURI's revenue ramp-up offsetting the increased operating expenses and reducing the net loss.

Keywords

UroGen Pharma, URGN, ZUSDURI, JELMYTO, LG-IR-NMIBC, LG-UTUC, Urothelial Cancer, Biotech, FDA Approval, Financial Results, Q4 2025, Full Year 2025, Pharmakon Advisors, Debt Refinancing, UGN-103, UGN-104, UGN-501, Clinical Trials, NDA Submission, Oncology, RTGel technology, Non-muscle invasive bladder cancer, Upper tract urothelial cancer